\nTNF Pharmaceuticals, Inc. (Nasdaq: TNFA<\/a>) (\u201cQ\/C\u201d or the \u201cCompany\u201d) today announced that it has changed its corporate name to Q\/C Technologies, Inc. and will begin trading under the new ticker symbol \u201cQCLS\u201d on the Nasdaq Capital Market, effective as of the market open<\/a> on Thursday, September 25, 2025. Until then, the Company\u2019s common stock will continue to trade under its current ticker symbol \u201cTNFA.\u201d<\/p>\n
\nThe new name Q\/C Technologies represents the Company\u2019s recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver\u2019s light-speed laser processing unit (LPU), the world\u2019s first light and laser-based computing system, for application in the cryptocurrency vertical.<\/p>\n
\nBy harnessing the unique physical properties of light in an innovative computing paradigm, the LPUs can reduce energy consumption by up to 90% while outperforming traditional GPUs and even quantum computing in both speed and efficiency. In addition to these performance gains, Lightsolver\u2019s architecture is designed to improve security for blockchain operations, offering a more sustainable and resilient foundation for the cryptocurrency industry. Together, these advantages are expected to position the Company to be at the forefront of innovation in blockchain infrastructure.<\/p>\n
\n\u201cOur new name and identity better reflect the Company\u2019s future,\u201d said Joshua Silverman, Chairman of Q\/C Technologies. \u201cWith exclusive rights to LightSolver\u2019s innovative computing platform for the crypto vertical, we are advancing a first-mover strategy in a trillion-dollar industry under immense pressure to evolve profitably and at scale. We believe that this transformation will position us to create significant value for our shareholders.\u201d<\/p>\n
\nIn connection with the name change and stock symbol change, no action is required from current shareholders and the Company\u2019s CUSIP number will remain the same.<\/p>\n
\nThe Company also noted that it continues to evaluate strategic options for its legacy therapeutic programs, isomyosamine and Supera-CBD, with the goal of maximizing value from these assets as it pivots into next-generation computing and blockchain infrastructure.<\/p>\n
\nAbout Q\/C Technologies (formerly TNF Pharmaceuticals)<\/b><\/p>\n
\nQ\/C Technologies is pioneering the next generation of energy-efficient blockchain infrastructure. <\/b>Through a licensing agreement with LightSolver, Q\/C holds exclusive rights to the use of innovative quantum-inspired laser-based processing units (LPUs) that solve compute-intensive combinatorial and physical problems at the speed of light. Q\/C bridges a disruptive computing paradigm for high-speed photonic computing with cryptocurrency infrastructure development at scale, unlocking unprecedented performance and sustainability for next generation blockchain applications.<\/p>\n
\nCautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n
\nThis press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cwill,\u201d \u201cwould\u2019\u2019 and other similar expressions are intended to identify these forward-looking statements and include statements related to the expected benefits from the licensing agreement with LightSolver and performance of LightSolver\u2019s technology. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company\u2019s ability to maintain compliance with the Nasdaq Stock Market\u2019s listing standards; the Company\u2019s ability to create value from its pharmaceutical candidates; the amount of funds the Company requires for the commercial development of its licensed technology and maintenance of its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company\u2019s ability to retain and attract senior management and other key employees; the Company\u2019s ability to quickly and effectively respond to new technological developments; and the Company\u2019s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company\u2019s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n
<\/p>\n